Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | April 23, 2019 | April 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 23, 2019 · Filed April 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 169,935 |
Ending reported balance
After 2019-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-23 · Exercise / conversion · Acquired 56,000 · Balance 225,935 Row 2 · 2019-04-23 · Sale · Disposed 56,000 · Balance 169,935 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 113,227 |
Reported balance
After 2019-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-23 · Exercise / conversion · Disposed 56,000 · Balance 113,227 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,698 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,698 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 53 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 53 F2: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019.
F2: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2008 Filed Feb 20, 2008 23:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 78,700 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011826 · a4.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,700 Underlying: Common shares · 78,700 shares Expires 2018-02-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,234 on 02/15/2009, 26,233 on 02/15/2010, and 26,233 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,700 | $55.56 | $1,094,532.00 |
DisclosureSEC source: 0001104659-08-011826 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,021 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,683 | $0.00 Strike: $56.34 | $0.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · derivative · entry 8 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,683 Underlying: common shares · 1,683 shares Expires 2010-02-10 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 23,617 | $0.00 Strike: $56.34 | $0.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,617 Underlying: common shares · 23,617 shares Expires 2009-02-11 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,993 | $0.00 Strike: $43.25 | $0.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731 Underlying: common shares · 1,993 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 28,485 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 28,485 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 25,300 | $56.34 | $1,425,402.00 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,321 Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,993 | $43.25 | $86,197.25 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2008 Filed Feb 14, 2008 17:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 28,485 | $42.50 | $1,210,549.83 |
DisclosureSEC source: 0001104659-08-010516 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,156 | $0.00 Strike: $50.95 | $0.00 |
DisclosureSEC source: 0001104659-08-009511 · a4.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,156 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,556 | $56.76 | $599,158.56 |
DisclosureSEC source: 0001104659-08-009511 · a4.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,143 Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $56.77 | $34,062.00 |
DisclosureSEC source: 0001104659-08-009511 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,699 Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,156 | $50.95 | $568,398.20 |
DisclosureSEC source: 0001104659-08-009511 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2007 Filed Dec 5, 2007 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,196 | $0.00 Strike: $57.51 | $0.00 |
DisclosureSEC source: 0001104659-07-087206 · a4.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,196 Underlying: Common shares · 1,196 shares Expires 2009-02-11 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| December 03, 2007 Filed Dec 5, 2007 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,420 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001104659-07-087206 · a4.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,485 Underlying: Common shares · 1,420 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| December 03, 2007 Filed Dec 5, 2007 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,196 | $57.51 | $68,781.96 |
DisclosureSEC source: 0001104659-07-087206 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,143 Read SEC document |
| December 03, 2007 Filed Dec 5, 2007 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,420 | $42.50 | $60,346.88 |
DisclosureSEC source: 0001104659-07-087206 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2007 Filed Sep 22, 2007 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,762 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001104659-07-070637 · a4.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,762 Underlying: common shares · 1,762 shares Expires 2009-02-11 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 19, 2007 Filed Sep 22, 2007 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,015 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001104659-07-070637 · a4.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,905 Underlying: common shares · 2,015 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 19, 2007 Filed Sep 22, 2007 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,762 | $53.60 | $94,443.20 |
DisclosureSEC source: 0001104659-07-070637 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,919 Read SEC document |
| September 19, 2007 Filed Sep 22, 2007 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,015 | $42.50 | $85,633.07 |
DisclosureSEC source: 0001104659-07-070637 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2007 Filed Sep 13, 2007 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,000 | $52.46 | $419,648.00 |
DisclosureSEC source: 0001104659-07-068940 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,666 Read SEC document |
| August 21, 2007 Filed Aug 23, 2007 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 15,116 | $0.00 Strike: $52.39 | $0.00 |
DisclosureSEC source: 0001104659-07-064609 · a4.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,116 Underlying: common shares · 15,116 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 21, 2007 Filed Aug 23, 2007 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,400 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-07-064609 · a4.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454 Underlying: common shares · 17,400 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 21, 2007 Filed Aug 23, 2007 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 15,116 | $52.39 | $791,927.24 |
DisclosureSEC source: 0001104659-07-064609 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,666 Read SEC document |
| August 21, 2007 Filed Aug 23, 2007 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,400 | $41.03 | $713,951.58 |
DisclosureSEC source: 0001104659-07-064609 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 20:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 5,816 | $0.00 Strike: $53.12 | $0.00 |
DisclosureSEC source: 0001104659-07-060981 · a4.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,816 Underlying: common shares · 5,816 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 20:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,746 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-07-060981 · a4.xml · derivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,854 Underlying: common shares · 6,746 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 20:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,816 | $53.12 | $308,945.92 |
DisclosureSEC source: 0001104659-07-060981 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,382 Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 20:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 6,746 | $41.03 | $276,799.85 |
DisclosureSEC source: 0001104659-07-060981 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2007 Filed Aug 6, 2007 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 4,549 | $0.00 Strike: $50.95 | $0.00 |
DisclosureSEC source: 0001104659-07-059246 · a4.xml · derivative · entry 8 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,549 Underlying: common shares · 4,549 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 02, 2007 Filed Aug 6, 2007 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 11,156 | $0.00 Strike: $50.95 | $0.00 |
DisclosureSEC source: 0001104659-07-059246 · a4.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,156 Underlying: common shares · 11,156 shares Expires 2008-02-12 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 02, 2007 Filed Aug 6, 2007 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,763 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-07-059246 · a4.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 Underlying: common shares · 5,763 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 02, 2007 Filed Aug 6, 2007 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 14,258 | $0.00 Strike: $34.77 | $0.00 |
DisclosureSEC source: 0001104659-07-059246 · a4.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 14,258 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 02, 2007 Filed Aug 6, 2007 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 15,705 | $50.95 | $800,169.75 |
DisclosureSEC source: 0001104659-07-059246 · a4.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,452 Read SEC document |
| August 02, 2007 Filed Aug 6, 2007 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,763 | $33.23 | $191,512.56 |
DisclosureSEC source: 0001104659-07-059246 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2007 Filed Aug 6, 2007 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 14,258 | $34.77 | $495,789.16 |
DisclosureSEC source: 0001104659-07-059246 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2007 Filed Jun 4, 2007 18:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 684 | $56.35 | $38,543.40 |
DisclosureSEC source: 0001104659-07-044919 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,136 Read SEC document |
| February 20, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,000 | $52.41 | $524,140.00 |
DisclosureSEC source: 0001104659-07-012364 · a4.xml · nonDerivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,820 Read SEC document |
| February 20, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,381 | $52.49 | $72,488.69 |
DisclosureSEC source: 0001104659-07-012364 · a4.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,820 Read SEC document |
| February 18, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 539 | $52.49 | $28,292.11 |
DisclosureSEC source: 0001104659-07-012364 · a4.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,201 Read SEC document |
| February 17, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,486 | $52.49 | $182,980.14 |
DisclosureSEC source: 0001104659-07-012364 · a4.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,740 Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,000 | $0.00 Strike: $52.54 | $0.00 |
DisclosureSEC source: 0001104659-07-012364 · a4.xml · derivative · entry 9 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common shares · 83,000 shares Expires 2017-02-15 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 27,667 on 02/16/2008, 27,667 on 02/16/2009, and 27,666 on 02/16/2010. Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,000 | $52.54 | $893,180.00 |
DisclosureSEC source: 0001104659-07-012364 · a4.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,226 F2 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 1996 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,400 | $52.54 | $1,071,816.00 |
DisclosureSEC source: 0001104659-07-012364 · a4.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,226 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2007 Filed Feb 20, 2007 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,918 | $52.70 | $311,878.60 |
DisclosureSEC source: 0001104659-07-012364 · a4.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,826 Read SEC document |
| February 01, 2007 Filed Feb 5, 2007 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 21,975 | $0.00 Strike: $53.00 | $0.00 |
DisclosureSEC source: 0001104659-07-007299 · a4.xml · derivative · entry 8 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,975 Underlying: Common shares · 21,975 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 01, 2007 Filed Feb 5, 2007 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,304 | $0.00 Strike: $47.82 | $0.00 |
DisclosureSEC source: 0001104659-07-007299 · a4.xml · derivative · entry 7 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,304 shares Expires 2007-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 01, 2007 Filed Feb 5, 2007 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 29,822 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-07-007299 · a4.xml · derivative · entry 6 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,813 Underlying: Common shares · 29,822 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 01, 2007 Filed Feb 5, 2007 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,304 | $52.86 | $68,930.74 |
DisclosureSEC source: 0001104659-07-007299 · a4.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,744 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.